Reports
Reports
Sale
The global cell therapy market value was USD 13.8 billion in 2022, driven by the increasing demand for regenerative therapies structure across the globe. The market size is anticipated to grow at a CAGR of 18.1% during the forecast period of 2023-2031 to achieve a value of USD 61.2 billion by 2031.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The global market for cell therapy is being driven by the increasing research and development (R&D) activities in the medical industry. Cell therapy is increasingly being used to treat patients with cancer, weakened immune systems, infectious diseases, and neurological disorders, which, in turn, surging its demand. Further, the COVID-19 pandemic is expected to positively impact the pharmaceutical and biotechnology-based research projects, including cell therapy. As the SARS-CoV-2 virus critically damages the lungs and immune system of the infected patient, various cell therapies are increasingly being explored as a potential treatment for the novel disease. Moreover, cell therapy can substantially improve survival rates of end-stage patients with acute respiratory distress syndrome (ARSD) associated with SARS-CoV-2, which is providing further impetus to the industry growth.
Europe holds a significant share of the overall cell therapy industry, with France and the United Kingdom being some of the dominant regional markets. The increasing research and development activities in France, owing to the presence of some of the leading biotech and research institutions of cell therapy, are aiding the market growth. In addition, the French biotech institutions, with government aid, are contributing to the development of innovative cell therapies. Moreover, the introduction of various favourable government initiatives to aid research activities is invigorating the industry growth, hence contributing to the overall market growth in the European region. For instance, the United Kingdom government initiated the Human-Induced Pluripotent Stem Cells Initiative (HipSCi) to bring preclinical, clinical and pharmacological work on stem cells under one institution and increase the accessibility of induced pluripotent stem cell (iPSC) resources to identify new mechanisms.
Cell therapy refers to a medical treatment in which ailing or dysfunctional cells are replaced with healthy and functional cells. The therapy aims at reducing or curing symptoms of diseases by restoring and altering certain sets of cells or by using cells to carry a remedy through the body. These cells may either be derived from the patient (autologous cells) or a donor (allogeneic cells). The cells are cultivated outside the body before transplanting into the patient.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Based on type, the market is divided into:
On the basis of therapy, the cell therapy industry is categorised into:
Based on application, the market is segmented into:
The EMR report looks into the regional market of cell therapy like North America, Latin America, the Asia Pacific, Europe, and the Middle East and Africa.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
With the growth in discoveries and innovations taking place around the globe, the healthcare sector is flourishing rapidly, which, in turn, is aiding the growth of the cell therapy industry. Cell therapies are becoming an ideal choice for treatment due to their high success rate, which is expected to fuel the market growth further. Various innovative cell therapies are emerging as a promising treatment for cancer and other diseases and are supporting the overall market growth. Increasing investments in the field of cell therapy, growing technological advancements, and rising cases of diseases such as cancer and cardiac abnormalities are also driving the growth of the industry.
The rapid expansion of the cell therapy industry to enhance the accessibility and functionality of cell therapies while reducing toxicity is anticipated to propel the market growth. The development of effective treatment of solid tumours is likely to be another breakthrough for cell-based therapies, which is expected to positively impact the market development in the coming years. Furthermore, the increasing investments for the research and development (R&D) activities to minimise costs during the manufacturing process while eliminating the requirement of a specialised structure is estimated to invigorate the growth of the cell therapy industry. The potential for cell therapy to treat major diseases such as cancer, anaemia, and Alzheimer’s disease, among others, is projected to further strengthen the cell therapy industry in the forecast period.
The report presents a detailed analysis of the following key players in the global cell therapy market, looking into their capacity, market share, and latest developments like capacity expansions, plant turnabouts and mergers and acquisitions.
The comprehensive report looks at the micro and macro aspects of the industry. The EMR report gives an in-depth insight into the market by providing a SWOT analysis as well as an analysis of the Porter’s Five Forces Model.
REPORT FEATURES | DETAILS |
---|---|
Base Year | 2022 |
Historical Period | 2016-2022 |
Forecast Period | 2023-2031 |
Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
Breakup by Cell Type |
|
Breakup by Therapy Type |
|
Breakup by Therapeutic Area |
|
Breakup by End User |
|
Breakup by Region |
|
Market Dynamics |
|
Supplier Landscape |
|
Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Cell Therapy Market Overview
3.1 Global Cell Therapy Market Historical Value (2016-2022)
3.2 Global Cell Therapy Market Forecast Value (2023-2031)
4 Global Cell Therapy Market Landscape
4.1 Global Cell Therapy Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Cell Therapy Product Landscape
4.2.1 Analysis by Cell Type
4.2.2 Analysis by Therapy Antigen
4.2.3 Analysis by End User
5 Global Cell Therapy Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Cell Therapy Market Segmentation
6.1 Global Cell Therapy Market by Cell Type
6.1.1 Market Overview
6.1.2 Stem Cell
6.1.2.1 Bone Marrow
6.1.2.2 Blood
6.1.2.3 Umbilical Cord
6.1.2.4 Adipose Derived Stem Cell
6.1.2.5 Others (Placenta, and Non-Specific Cells)
6.1.3 Non-Stem Cell
6.2 Global Cell Therapy Market by Therapy Type
6.2.1 Market Overview
6.2.2 Autologous
6.2.3 Allogeneic
6.3 Global Cell Therapy Market by Therapeutic Area
6.3.1 Market Overview
6.3.2 Musculoskeletal disorders
6.3.3 Cardiovascular diseases
6.3.4 Neurological disorders
6.3.5 Oncological disorders
6.3.6 Dermatology
6.3.7 Inflammatory and Autoimmune disorders
6.3.8 Others
6.4 Global Cell Therapy Market by End User
6.4.1 Market Overview
6.4.2 Hospitals and Clinics
6.4.3 Regenerative Medicine Centers
6.4.4 Diagnostic and Research Centers
6.4.5 Others
6.5 Global Cell Therapy Market by Region
6.5.1 Market Overview
6.5.2 North America
6.5.3 Europe
6.5.4 Asia Pacific
6.5.5 Latin America
6.5.6 Middle East and Africa
7 North America Cell Therapy Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe Cell Therapy Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific Cell Therapy Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.5 ASEAN
9.6 Australia
9.7 Others
10 Latin America Cell Therapy Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa Cell Therapy Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by NIH Departments
13.7 Analysis by Recipient Organization
14 Clinical Trials Analysis
14.1 Analysis by Trial Registration Year
14.2 Analysis by Trial Status
14.3 Analysis by Trial Phase
14.4 Analysis by Therapeutic Area
14.5 Analysis by Geography
15 Funding Analysis
15.1 Analysis by Funding Instances
15.2 Analysis by Type of Funding
15.3 Analysis by Funding Amount
15.4 Analysis by Leading Players
15.5 Analysis by Leading Investors
15.6 Analysis by Geography
16 Partnership and Collaborations Analysis
16.1 Analysis by Partnership Instances
16.2 Analysis by Type of Partnership
16.3 Analysis by Leading Players
16.4 Analysis by Geography
17 Regulatory Framework
17.1 Regulatory Overview
17.1.1 US FDA
17.1.2 EU EMA
17.1.3 INDIA CDSCO
17.1.4 JAPAN PMDA
17.1.5 Others
18 Supplier Landscape
18.1 Vericel Corporation
18.1.1 Financial Analysis
18.1.2 Product Portfolio
18.1.3 Demographic Reach and Achievements
18.1.4 Mergers and Acquisitions
18.1.5 Certifications
18.2 Kolon TissueGene Inc.
18.2.1 Financial Analysis
18.2.2 Product Portfolio
18.2.3 Demographic Reach and Achievements
18.2.4 Mergers and Acquisitions
18.2.5 Certifications
18.3 JCR Pharmaceuticals Co. Ltd.
18.3.1 Financial Analysis
18.3.2 Product Portfolio
18.3.3 Demographic Reach and Achievements
18.3.4 Mergers and Acquisitions
18.3.5 Certifications
18.4 MEDIPOST Co. Ltd.
18.4.1 Financial Analysis
18.4.2 Product Portfolio
18.4.3 Demographic Reach and Achievements
18.4.4 Mergers and Acquisitions
18.4.5 Certifications
18.5 Osiris
18.5.1 Financial Analysis
18.5.2 Product Portfolio
18.5.3 Demographic Reach and Achievements
18.5.4 Mergers and Acquisitions
18.5.5 Certifications
18.6 Stemedica Cell Technologies Inc.
18.6.1 Financial Analysis
18.6.2 Product Portfolio
18.6.3 Demographic Reach and Achievements
18.6.4 Mergers and Acquisitions
18.6.5 Certifications
18.7 NuVasive Inc.
18.7.1 Financial Analysis
18.7.2 Product Portfolio
18.7.3 Demographic Reach and Achievements
18.7.4 Mergers and Acquisitions
18.7.5 Certifications
18.8 Fibrocell Science Inc.
18.8.1 Financial Analysis
18.8.2 Product Portfolio
18.8.3 Demographic Reach and Achievements
18.8.4 Mergers and Acquisitions
18.8.5 Certifications
18.8.6 Cells for Cells
18.8.7 Financial Analysis
18.8.8 Product Portfolio
18.8.9 Demographic Reach and Achievements
18.8.10 Mergers and Acquisitions
18.8.11 Certifications
18.9 PHARMICELL Co. Ltd
18.9.1 Financial Analysis
18.9.2 Product Portfolio
18.9.3 Demographic Reach and Achievements
18.9.4 Mergers and Acquisitions
18.9.5 Certifications
18.10 ANTEROGEN.CO.LTD.
18.10.1 Financial Analysis
18.10.2 Product Portfolio
18.10.3 Demographic Reach and Achievements
18.10.4 Mergers and Acquisitions
18.10.5 Certifications
18.11 Novartis AG,
18.11.1 Financial Analysis
18.11.2 Product Portfolio
18.11.3 Demographic Reach and Achievements
18.11.4 Mergers and Acquisitions
18.11.5 Certifications
18.12 CELGENE CORPO RATION
18.12.1 Financial Analysis
18.12.2 Product Portfolio
18.12.3 Demographic Reach and Achievements
18.12.4 Mergers and Acquisitions
18.12.5 Certifications
18.13 Allogene Therapeutics Inc.
18.13.1 Financial Analysis
18.13.2 Product Portfolio
18.13.3 Demographic Reach and Achievements
18.13.4 Mergers and Acquisitions
18.13.5 Certifications
18.14 Stempeutics Research Pvt. Ltd
18.14.1 Financial Analysis
18.14.2 Product Portfolio
18.14.3 Demographic Reach and Achievements
18.14.4 Mergers and Acquisitions
18.14.5 Certifications
19 Global Cell Therapy Market - Distribution Model (Additional Insight)
19.1 Overview
19.2 Potential Distributors
19.3 Key Parameters for Distribution Partner Assessment
20 Key Opinion Leaders (KOL) Insights (Additional Insight)
21 Company Competitiveness Analysis (Additional Insight)
21.1 Very Small Companies
21.2 Small Companies
21.3 Mid-Sized Companies
21.4 Large Companies
21.5 Very Large Companies
22 Payment Methods (Additional Insight)
22.1 Government Funded
22.2 Private Insurance
22.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
The global cell therapy market was valued at USD 13.8 billion in 2022.
The market is expected to grow at a CAGR of 18.1% from 2023 to 2031 to reach a value of USD 61.2 billion by 2031.
The cell therapy industry is being aided by the introduction of various favourable government initiatives and the rising investment in the healthcare sector for the integration of technological advancements in biotechnological researches.
The industry is anticipated to be driven by the use of cell therapies as effective COVID-19 and cancer treatments, the rising cost-effectiveness of cell therapy, and the increasing investments in research and development (R&D) activities.
The major regions in the industry are North America, Latin America, the Asia Pacific, Europe, and the Middle East and Africa.
The major types of cell therapy in the market are autologous and allogeneic.
Mesenchymal stem cell therapy, fibroblast cell therapy, and hematopoietic stem cell therapy are the leading therapy segments in the cell therapy industry.
The significant application segments of cell therapy in the market are musculoskeletal, malignancies, cardiovascular, and dermatology and wounds.
They key players in the market are Tego Science, Chiesi Farmaceutici S.p.A, and Pharmicell Co., Ltd, among others.
Mini Report
Single User License
Five User License
Corporate License
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.